Eyestem - RetinAI Partners to Redefine the Ophthalmology Research
Written by Shaveta Arora, Arushi Sharma
Eyestem Research, a biotechnology firm based in Bangalore, has joined forces with Ikerian AG and RetinAI Inc., a US-based company specializing in clinical and imaging data management software and AI analytics.
Eyestem Research, a Bangalore-based biotechnology firm, has formed a strategic alliance with Ikerian AG and RetinAI Inc., a US-based firm known for its expertise in clinical and imaging data management software and AI-driven analytics.
Eyestem is utilizing RetinAI's Discovery platform and AI tools to develop Eyecyte-RPE, a revolutionary cell therapy for treating geographic atrophy.
Dr Jogin Desai, Founder and CEO of Eyestem said, “This collaboration with RetinAI marks a significant milestone in our journey. Their sophisticated AI tools and the RetinAI Discovery platform integrate perfectly with our vision, potentially shortening the timelines for our clinical trials and enhancing the accuracy of our analyses. This is not just a partnership; it’s a confluence of high-end biotech innovation and cutting-edge artificial intelligence aiming to rewrite the narrative for patients affected by geographic atrophy worldwide.”
Dr Carlos Ciller, CEO of RetinAI said, “We are excited to partner with Eyestem, known for its forward-thinking approach to biotechnology and cell therapy. Our AI-driven Discovery platform is poised to significantly accelerate research and provide enhanced insights into disease progression and outcomes. Together, we’re confident that this synergy will not only enrich insights in the development of novel treatments but also manifest in delivering life-altering solutions faster to individuals affected by retinal diseases globally.”
Geographic atrophy, an advanced stage of dry age-related macular degeneration, affects 200 million people globally, causing irreversible vision loss, and its prevalence is increasing due to an aging population.
Eyestem is set to launch Phase I/IIa clinical trials for Eyecyte-RPE, a multicenter, dose escalation, and expansion study aimed at evaluating its safety and effectiveness in addressing geographic atrophy. The trial will use RetinAI's Discovery platform for data management and image analysis, and its advanced segmentation model for real-time insights into clinical endpoints.